Recurrence of inflammatory lesions is frequent in patients undergoing ileal resection for Crohn’s disease (CD), although there is not a single clinical risk factor that can be used as a perfect predictor of early postoperative endoscopic recurrence. The researchers of this study sought a microbiotic biomarker to predict recurrence. To this end they catalogued the ileal mucosa-associated microbiota by using ribosomal 16S sequencing at the time of surgery and/or at the time of postoperative endoscopic evaluation (about 6 to 12 months after surgery) in 201 patients from 9 centres in the prospective REMIND cohort. Not surprisingly, antibiotics treatment within one month before surgery had a dramatic impact on microbiota composition (P< 0.0001) and diversity (Shannon index mean 4.3±0.1 vs 3.7±0.2, P=0.006).
The ileal mucosa-associated microbiota exhibited major changes following CD surgery that differed between the time of surgery and the time of postoperative endoscopic evaluation. Specifically, changes included a decrease in beta diversity and a decrease in the Gammaproteobacteria class, an increase in the Alphaproteobacteria class, a decrease in the Bacilli class and an increase in the Clostridiales order.
Compared with patients who did not recur, however, endoscopic recurrence was associated with a high abundance of bacteria from the Gammaproteobacteria, the Ruminococcus gnavus group and Corynebacterium genera (Area under the curve: 97.1% [93.8%-100%] and 81.0% [60.8%-100%] in the whole population and in the validation set respectively). In contrast, patients without endoscopic recurrence at 6 to 12 months after surgery showed increased levels of bacteria from the Lachnospiraceae families, such as the Roseburia, Blautia, and Dorea genera.
In conclusion, ileocecal resection and endoscopic recurrence are associated with changes in ileal mucosa-associated microbiota, which may be applied for prognostication.
- Sokol H et al. UEG Week 2019, Abstract OP209.
Posted on
Previous Article
« Early stages of gastric metaplasia: molecular profiling Next Article
Ustekinumab is safe and effective in ulcerative colitis: 2-year data »
« Early stages of gastric metaplasia: molecular profiling Next Article
Ustekinumab is safe and effective in ulcerative colitis: 2-year data »
Table of Contents: UEGW 2019
Featured articles
Interview with UEG President Prof. Paul Fockens
Upper GI Disorders
Locally active corticosteroid promising in eosinophilic oesophagitis
First-in-human radiofrequency vapor ablation in Barrett’s oesophagus
Irritable Bowel Syndrome
Faecal microbiota transplantation is effective for irritable bowel syndrome
Human milk oligosaccharides improve IBS symptoms
Inflammatory Bowel Disease
Ustekinumab is safe and effective in ulcerative colitis: 2-year data
Decreased microvilli length in CD patients
Phase 2 data shows benefit for mirikizumab in CD patients
Subcutaneous ustekinumab as maintenance therapy in UC
First evidence of long-term efficacy of ABX464 in ulcerative colitis
New treatment may reverse coeliac disease
IBD prevalence 3 times higher than estimated and expected to rise
Microbiome and Microbiota
Early stages of gastric metaplasia: molecular profiling
Plant-based foods and Mediterranean diet associated with healthy gut microbiome
Antibiotic resistance in H. pylori has doubled over last 20 years
Pancreatitis
New model predicts recurrence of acute biliary pancreatitis
Hepatology
Restrictive strategy for cholecystectomy selection does not reduce pain, but does reduce surgery
β-blockers may halt cirrhosis progression: PREDESCI trial
Obeticholic acid prevents liver fibrosis from NASH
Oncology
Metal stents are better than plastic for endoscopic biliary drainage
Ramosetron relieves low anterior resection syndrome
Immunonutrition during neoadjuvant oesophagogastric cancer therapy: no benefit
Endoscopy
EUS-guided histological specimens from the pancreatic cyst wall
Digital single-operator cholangioscopy more sensitive than endoscopic retrograde cholangiopancreatography
New single-use duodenoscope well-liked by endoscopists
Related Articles
October 23, 2019
Global burden of digestive diseases reveals alarming trends
October 23, 2019
Half of common medications wreak havoc on gut microbiome
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com